蔡芝蓉 高三下 (2016/07/26) Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.